Besides that, there is various studies discussing that new OAD including Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Antagonist (GLP-1 RA) may have advantageous effects on preventing the progression of prediabetes. Here, GLP1R is linked to prediabetes syndrome.